Genotype frequencies of acute, subacute, late, and very late stent thrombosis.

<p>There was no difference in the genotype distribution of <i>PON1</i> Q192R and <i>CYP2C19</i> between acute, subacute, late, and very late ST, with a <i>P</i> value of 0.549 and 0.747, respectively.</p

Percentage of mutant allele carriers of <i>CYP</i> 2C19 and <i>PON1</i> and <i>ABCB1</i> polymorphisms.

<p>Graph showing the percentage of mutant allele carriers for cytochrome P450 (<i>CYP</i>) and paraoxonase-1 (<i>PON1</i>) and ATP-binding cassette transporter (<i>ABCB1</i>) polymorphisms in stent thrombosis (ST) group (blue) and non-ST group (red). The carrier percentage for the <i>CYP</i> 2C19*2 mutant allele is significantly different between the ST and non-ST groups (75% vs. 40%; carrier odds ratio [OR 4.2; 95% confidence interval [CI], 1.263–9.544; <i>P</i> = 0.031), with a high carrier percentage in the ST group.</p

Baseline clinical characteristics.

*<p>ST, stent thrombosis.</p>†<p>CRP, C-reactive protein.</p><p>Baseline clinical characteristics of the stent thrombosis and non-stent thrombosis groups.</p

Results of multivariable logistic regression for genotype carriers in predicting stent thrombosis.

*<p>Unadjusted odds ratios (ORs): <i>CYP</i> 2C19*2, OR, 4.50 (1.363–14.844), <i>P</i> = 0.028; <i>PON1</i> Q129R, OR, 0.74 (0.252–2.171), <i>P</i> = 0.697; <i>ABCB1</i> C3435T rs1045642, OR, 2.22 (0.674–7.293), <i>P</i> = 0.212.</p>†<p>CI, confidence interval.</p

Additional file 1: Table S1. of Genome-wide association and replication study of anti-tuberculosis drugs-induced liver toxicity

Top fifteen SNPs in the GWAS of ATDILI. Table S2. Top fifteen SNPs in the replication study of ATDILI. Table S3. Top SNPs in the GWAS of the pattern of ATDILI. Table S4. Top SNPs for GWAS of ATDILI in genes related to autoimmune diseases, oxidative stress, pharmacokinetic, and HLA region. (PDF 57 kb